ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Scottish Medicines Consortium tisagenlecleucel (Kymriah)
March 12, 2019For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. -
Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis
December 04, 2018Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients. -
CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma
December 04, 2018In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lym
Pharma Sources Insight January 2025
